

Cellnovo Appoints Erwan Martin as Chief Financial Officer

Paris, France, 3 April 2017 - Cellnovo Group ("Cellnovo" CLNV: EN Paris), a medical technology company marketing the first mobile, connected, all-in-one diabetes management system, announces the appointment of Erwan Martin as Chief Financial Officer. Erwan replaces Thierry Moulin who has left the company to pursue other interests.

Before joining Cellnovo, Erwan Martin, 48 years old, was Chief Financial Officer of Genomic Vision (Euronext: GV), a position he had held since 2009. He was also VP Corporate Development until 2015, undertaking financing operations such as the Company's initial public offering. With over 20 years of professional experience in the field of finance and biotechnology, Erwan Martin is an expert in finance and corporate development. He began his career as an analyst, then worked as a project manager for ten years at Syndex, a firm specialising in auditing and consulting for works councils. In 2000, he co-founded Cytomics Pharmaceuticals, a biotechnology company specialising in the discovery of new medicines, where he was a member of the Management Board and Chief Financial Officer. He supervised the Company's development, particularly by supporting several financing rounds worth a total of more than €20 million. Erwan Martin holds an MBA from Warwick Business School (UK) and is also a graduate of the *Ecole Supérieure de Commerce* (ESC) in Toulouse.

Sophie Baratte, Chief Executive Officer of Cellnovo, commented: *"I am delighted to welcome Erwan as Cellnovo's new Chief Financial Officer. He will significantly strengthen the management of our company. His substantial experience in the development of growing companies in the medical sector and financial markets will no doubt bring value to Cellnovo as we continue to progress through the development and marketing of our unique diabetes management system. I would also like to thank Thierry for his very active contribution to the Company's progress over the last year."*

About Cellnovo

An independent medical technology company specialising in diabetes, Cellnovo has developed and markets the first mobile, connected, all-in-one diabetes management system that helps make life easier for patients. Compact, intuitive and entirely connected, Cellnovo's insulin pump comprises a mobile touchscreen controller with an integrated blood-glucose meter. This unique device allows optimal management of insulin injections whilst ensuring extensive freedom of movement and peace of mind for patients. Thanks to the automatic transmission of data, it also allows the patient's condition to be continually monitored by family members and healthcare professionals in real time. Cellnovo is currently participating in several major Artificial Pancreas projects with Diabeloop, TypeZero and Horizon 2020 to develop automated insulin delivery systems.

For further information please visit www.cellnovo.com

About the Cellnovo Diabetes Management System

Compact, intuitive and entirely connected, Cellnovo's insulin pump comprises a mobile touchscreen controller with an integrated blood-glucose meter. This unique device allows optimal management of insulin injections with drop-by-drop precision, whilst ensuring extensive freedom of movement and peace of mind for patients. Thanks to the automatic transmission of data, it also allows the patient's condition to be continually monitored by family members and healthcare professionals in real time.

Cellnovo is listed on Euronext, Compartment C
ISIN: FR0012633360 – Ticker: CLNV





The First Connected All-in-one Diabetes Management System

Contact

Cellnovo

Chief Executive Officer
Sophie Baratte
investors@cellnovo.com

NewCap

Investor Relations
Tristan Roquet Montégon
+ 33 1 44 71 00 16

Media Relations in France
Nicolas Merigeau
+ 33 1 44 71 94 98
cellnovo@newcap.eu

Consilium Strategic Communications

Media Relations in United Kingdom
Chris Gardner, Chris Welsh, Laura Thornton
+44 20 3709 5700
cellnovo@consilium.com